

해외 바이오의약품 임상 현황 ('23년 10월 1주)

한국바이오의약품협회, 2023.10.10.

※ ClinicalTrials.gov에 등록된 국가별 바이오의약품 임상시험 목록(병용요법 포함)을 한국바이오의약품협회에서 주간 업데이트하여 제공합니다.

URL을 클릭하시면 세부 정보 페이지로 연결됩니다.

- 출처: ClinicalTrials.gov
- 모니터링 기간: 2023.10.02.~2023.10.08.
- 주간 업데이트 제공국가 : 미국, 유럽(영국, 프랑스, 독일), 중국, 일본

○ 미국 10건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06040320	Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)	Drug: Polatuzumab vedotin Drug: Rituximab Drug: CHP	Washington University School of Medicine	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06040320
NCT06003387	Efficacy and Safety of CSL222 (Etranacogene Dezaparovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)	Genetic: CSL222 (AAV5-hFIXco-Padua)	CSL Behring	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06003387
NCT05989828	A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer	Biological: Aldesleukin Biological: Anti-HLA-A2/NY-ESO-1 TCR-transduced Autologous T Lymphocytes Procedure: Biopsy Procedure: Biospecimen Collection Procedure: Computed Tomography Drug: Cyclophosphamide Procedure: Echocardiography Drug: Fludarabine Procedure: Leukapheresis Procedure: Magnetic Resonance Imaging Procedure: Mammogram Procedure: Multigated Acquisition Scan Procedure: Ultrasound Imaging	University of Southern California National Cancer Institute (NCI)	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05989828
NCT05672251	Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma	Procedure: Biopsy Procedure: Biospecimen Collection Procedure: Computed Tomography Biological: Loncastuximab Tesirine Biological: Mosunetuzumab Procedure: Positron Emission Tomography	City of Hope Medical Center National Cancer Institute (NCI)	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05672251
NCT05715281	Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial	Biological: Atezolizumab Procedure: Biopsy Procedure: Biospecimen Collection Procedure: Computed Tomography Procedure: Echocardiography Drug: Tiragolumab	National Cancer Institute (NCI)	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05715281
NCT05892718	A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors	Drug: HCB101	FBD Biologics Limited	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05892718
NCT05925127	Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines	Biological: NVX-CoV2373 (5μg) Biological: NVX-CoV2601 (5μg) Biological: NVX-CoV2601 (5μg) Biological: NVX-CoV2601 (35μg) Biological: NVX-CoV2601 (35μg) Biological: NVX-CoV2601 (50μg) Biological: Bivalent BA.4/5	Novavax	Phase 2 Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05925127
NCT06067230	A Study to Investigate the Immunogenicity and Safety of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in High-risk Adults	Biological: mRNA-1345	ModernaTX, Inc.	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06067230

해외 바이오의약품 임상 현황 ('23년 10월 1주)

한국바이오의약품협회, 2023.10.10.

○ 미국 10건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06062420	Phase 2 Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck	Drug: Dostarlimab Drug: Belrestotug Drug: GSK6097608	GlaxoSmithKline iTeos Therapeutics	Phase 2	
NCT05609630	Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.	Drug: Upadacitinib Drug: Tocilizumab	AbbVie	Phase 3	

○ 영국 1건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06067230	A Study to Investigate the Immunogenicity and Safety of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in High-risk Adults	Biological: mRNA-1345	ModernaTX, Inc.	Phase 3	

○ 프랑스 1건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06062420	Phase 2 Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck	Drug: Dostarlimab Drug: Belrestotug Drug: GSK6097608	GlaxoSmithKline iTeos Therapeutics	Phase 2	

○ 독일 2건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06069895	Investigation of Safety, Tolerability and Pharmacokinetics of Multiple Doses of NNC0113-6856 in Healthy Participants, Including a Subset of Healthy Japanese Participants	Drug: NNC0113-6856 Drug: Placebo	Novo Nordisk A/S	Phase 1	
NCT06062420	Phase 2 Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck	Drug: Dostarlimab Drug: Belrestotug Drug: GSK6097608	GlaxoSmithKline iTeos Therapeutics	Phase 2	

○ 중국 2건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06061146	Tislelizumab Plus Concurrent Chemoradiation in Older With ESCC	Drug: Arm A Radiation: Arm A Drug: Arm B Radiation: Arm B	Tianjin Medical University Cancer Institute and Hospital Sichuan Cancer Hospital and Research Institute Shanxi Province Cancer Hospital Henan Cancer Hospital Hunan Cancer Hospital The First Affiliated Hospital with Nanjing Medical University	Phase 2	
NCT05540275	Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent Glioblastoma	Drug: Tislelizumab plus Bevacizumab	Henan Provincial People's Hospital	Phase 2	

해외 바이오의약품 임상 현황 ('23년 10월 1주)

한국바이오의약품협회, 2023.10.10.

○ 일본 2건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05609630	Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.	Drug: Upadacitinib Drug: Tocilizumab	AbbVie	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05609630
NCT06062420	Phase 2 Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck	Drug: Dostarlimab Drug: Belrestotug Drug: GSK6097608	GlaxoSmithKline Teos Therapeutics	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06062420